ARCHIVES

FDA advisors vote against recommending Johnson & Johnson’s Zarnestra for treatment of AML in the elderly.

This article is from The Cancer Letter archive.

Vol. 31 No. 18 | May 6, 2005

Download PDF Visit The Full Archive

Related Articles

In Brief: Gene Therapy Pioneer Michael Blaese To Leave NIH For Biotechnology Firm

January 23, 1998

New Clinical Trials Monitoring Program To Site Visit PIs Every Three Years

July 30, 1982

ASCO Supports CT Scans For Colorectal Screening

November 25, 2005

In Brief: No End Of The Year Hassle His Time – NCI Full Appropriation for FY 1977 Released

November 19, 1976

Complete List of Recommendations by Centers Committee

October 18, 1996

Congress Ignores construction Fund Reprogramming

February 18, 1977